Drug Profile
MDX 44
Latest Information Update: 12 Sep 2003
Price :
$50
*
At a glance
- Originator Medarex
- Class Drug conjugates; Immunotoxins
- Mechanism of Action Macrophage inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Atopic dermatitis; Psoriasis
Most Recent Events
- 31 Dec 2002 Discontinued - Phase-I for Psoriasis in Netherlands (unspecified route)
- 31 Dec 2002 Discontinued - Preclinical for Atopic dermatitis in USA (unspecified route)
- 31 Dec 2002 Discontinued - Preclinical for Psoriasis in USA (unspecified route)